A novel pathogenic mutation of MeCP2 impairs chromatin association independent of protein levels

Authors:

Abstract
Loss-of-function mutations inMECP2cause Rett syndrome (RTT), a severe neurological disorder that mainly affects girls. Mutations inMECP2do occur in males occasionally and typically cause severe encephalopathy and premature lethality. Recently, we identified a missense mutation (c.353G>A, p.Gly118Glu [G118E]), which has never been seen before inMECP2, in a young boy who suffered from progressive motor dysfunction and developmental delay. To determine whether this variant caused the clinical symptoms and study its functional consequences, we established two disease models, including human neurons from patient-derived iPSCs and a knock-in mouse line. G118E mutation partially reduces MeCP2 abundance and its DNA binding, and G118E mice manifest RTT-like symptoms seen in the patient, affirming the pathogenicity of this mutation. Using live-cell and single-molecule imaging, we found that G118E mutation alters MeCP2's chromatin interaction properties in live neurons independently of its effect on protein levels. Here we report the generation and characterization of RTT models of a male hypomorphic variant and reveal new insight into the mechanism by which this pathological mutation affects MeCP2's chromatin dynamics. Our ability to quantify protein dynamics in disease models lays the foundation for harnessing high-resolution single-molecule imaging as the next frontier for developing innovative therapies for RTT and other diseases.
Funding Information
  • National Institutes of Health (5R01NS057819, R01NS100738, 1F32HD100048-01, P30 CA125123, S10 OD028591, P50HD103555)
  • Erasmus Exchange Extra UE Program
  • Centro Europeo Università e Ricerca
  • Foundation
  • Howard Hughes Medical Institute
  • Henry Engel Fund
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development